Massive Change in U.S. Treatment Guidelines
As with previous guidelines, the panel added to a growing list of drugs or combinations of drugs that should not be used for the initial therapy of HIV infection. In general, specific combinations are not recommended because of insufficient efficacy, drug interactions or insufficient information on how they work in people who have not previously used these medicines.
In recent years, there have been several studies of just one active drug (such as the use of a ritonavir-boosted protease inhibitor) in a regimen for maintenance therapy. That is, in clinical trials, a conventional triple-drug regimen is used to suppress viral load and raise CD4+ counts for one year, then participants are switched to one of these simple regimens for maintenance:
These regimens are being studied in clinical trials and are considered investigational and therefore not recommended by the panel.
Other combinations that are not recommended by the panel include the following:
This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.